Table 3:
Author (Year) |
Intervention | Setting | Design & Comparator | Estimated Catheter Days | Baseline CAUTI Rate | Effectiveness | Approach, Perspective, Year of Costs | Program Costs | CAUTI-related Costs | Incremental Net Cost | mQHES |
---|---|---|---|---|---|---|---|---|---|---|---|
Changes to Hospital CAUTI-Related Policies and Practices
| |||||||||||
Palmer 201947 | Catheterization tray, training program | U.K., 3 community hospitals | UCBA, SQ | NR | 13.3% of catheterized patients | IRR = 0.16 | Cost analysis, hospital, 2014 |
£5,440 for 3 hospitals | NR | -£33,000 for 3 hospitals | 87.5 |
| |||||||||||
Mitchell 201948,57 | Routine use of chlorhexidine prior insertion | Australia, 3 community hospitals | Model, SQ | NR | 4.55 / 1000 catheter-days | IRR = 0.06 (95% CI: 0.01 to 0.32) |
Cost analysis, hospital, 2018 |
AUD$89,012 per 100,000 catheter-izations | NR | −AUD$387,909 per 100,000 catheter- izations |
89.5 |
| |||||||||||
Cartwright 201841 | Catheterization tray, training program | U.K., 2 academic hospitals | UCBA, SQ | 14,586 | 102 CAUTI per 2 HPY | IRR = 0.21 | Cost analysis, hospital, 2015 |
−£40,000 per 2 HPY |
−£159,400 per 2 HPY |
NR | 72 |
| |||||||||||
Pashnik 201744 | Nurse-led teaching and evaluation | U.S., 1 academic hospital | UCBA, SQ | 49,359 | 1.3 / 1000 catheter-days | IRR = 0.70 | Cost analysis, hospital, 2016 |
$100,000 PH over 1.75 yr | $6,834 per CAUTI (1o data) | NR | 64.5 |
| |||||||||||
Anderson 201158 | Checklists, audit & feedback for CLABSI, CAUTI, VAP, MRSA | U.S., 24 community hospitals (23 eligible) |
UCBA, SQ |
282,915 | 4.4 / 1000 catheter-days | IRR 0.50 | Cost analysis, hospital, 2009 |
$20,000 to $40,000 PHPY | −$82,722 to −$159,902 PHPY |
−$7.9 to −$15.4 million for 24 hospitals over 5 years | 102 |
| |||||||||||
van den Broek 201135 | Removal reminder, ultrasound | Netherlands, 2 academic & 8 community hospitals | Time series, SQ |
15,820 | 12.6% of catheterized patients |
IRR 1.01 | Cost analysis, hospital, 2008 |
€2,638 per hospital plus −€5.37 per hospitalized patient |
$0 (not effective) |
NR | 101 |
| |||||||||||
Saint 200537 | Physician reminders re: catheters | U.S., 1 academic hospital | CBA, SQ |
NR | NR | Time catheterized: ↓7.6% vs. ↑15.1% | Cost analysis, hospital, 2003 |
$53,200 PHPY | −$53,449 PHPY |
−$249 PHPY |
82 |
Antimicrobial Catheters | |||||||||||
Pickard 201238 | Silver alloy catheter | U.K., 24 academic & community hospitals | RCT, PTFE-coated catheter |
20,596 | 12.6% of catheterized patients |
RD = −0.1%, IRR = 0.99 | Cost-effectiveness, health system, 2007 |
£5.38 per catheterized patient | £548 per CAUTI (1o data) | +£5.05 per catheterized patient | 113 |
| |||||||||||
Nitrofurazone catheter | 19,992 | RD = −2.1%, IRR = 0.84 | £4.19 per catheterized patient | −£7.10 per catheterized patient | |||||||
| |||||||||||
Rupp 200436 | Silver alloy catheter | U.S., 1 academic hospital | UCBA, uncoated catheter | 48,662 | 6.13 / 1000 catheter-days | IRR = 0.43 | Cost analysis, hospital, 2002 |
$64,794 PHPY | −$71,118 to −$549,377 PHPY |
−$5,811 to −$535,452 PHPY |
95.5 |
| |||||||||||
Lai 200239 | Silver alloy catheter | U.S., 1 academic hospital | UCBA, uncoated catheter | 62,855 | 4.9 / 1000 patient-days | IRR = 0.55 | Cost analysis, hospital, 1997 |
$120,000 PHPY | $1,214 per CAUTI (1o data) | −$142,315 PHPY |
97 |
| |||||||||||
Karchmer 200043 | Silver alloy catheter | U.S., 1 academic medical center | Randomized crossover, uncoated catheter | 112,846 | 3.00 / 1000 patient-days | IRR = 0.79 (95% CI: 0.63 to 0.99) | Cost analysis, hospital, 1997 |
$107,225 PHPY | −$121,681 to −$680,518 PHPY |
−$14,456 to −$573,293 PHPY |
103 |
| |||||||||||
Saint 200042 | Silver alloy catheter | Hypothetical cohort, 1 academic hospital | Model, uncoated catheter | 11,410 | 30 / 1000 catheterized patients |
IRR = 0.53 | Cost analysis, payer, 1998 |
$5.30 per catheterized patient | $374–402 + ($2041*0.04) per CAUTI (1o data) | −$4.09 per catheterized patient | 105.5 |
Both CAUTI-Related Policies & Practices and Antimicrobial Catheters | |||||||||||
Quinn 201540 | Silver alloy catheter, nurse-driven protocol | U.S., 1 community hospital | UCBA, SQ |
35,461 | 4.95 / 1000 catheter-days | IRR 0.08 (2012) | Cost analysis, hospital, 2009 |
$75,000 PHPY | $132,000 vs. $6,000 (2012) PHPY | NR | 87 |
| |||||||||||
Clarke 201359 | Silver alloy catheter, reminders, education | U.S, 1 community hospital | UCBA, SQ |
5,821 | 5.2 / 1000 catheter-days | IRR 0.29 | Cost analysis, Hospital, 2008 |
$23,924 PHPY | $1200 to $4700 per CAUTI (literature) | −$6,892 to −$96,772 PHPY |
77 |
Abbreviations: mQHES, Quality of Health Economics Studies Checklist; CAUTI, catheter-associated urinary tract infection; QI, quality improvement; U.S., United States; U.K., United Kingdom; SQ, status quo (usual care); RR, rate ratio; IRR, incidence rate ratio; RD, risk difference; CEA, cost-effectiveness, cost-benefit, and related analyses; RCT, randomized control trial; UCBA, uncontrolled before-after analysis; CBA, controlled before-after analysis; NR, not reported; PTFE, polytetrafluoroethylene; PHPY, per hospital per year